Safety and Efficacy of Propylene Glycol-Free Melphalan in Patients with AL Amyloidosis Undergoing Autologous Stem Cell Transplantation: Results of a phase II study: Propylene Glycol-Free Melphalan Conditioning for Autologous Stem Cell Transplantation for AL Amyloidosis.
暂无分享,去创建一个
Michelle H. Lee | G. Doros | V. Sanchorawala | J. Sloan | K. Quillen | A. Shelton | D. Brauneis | C. Edwards | Shayna R Sarosiek
[1] J. Berk,et al. Predictors of hematologic response and survival with stem cell transplantation in AL amyloidosis: A 25‐year longitudinal study , 2022, American journal of hematology.
[2] M. Boccadoro,et al. Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines , 2021, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.
[3] N. Powe,et al. New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race. , 2021, The New England journal of medicine.
[4] G. Doros,et al. Predictors and outcomes of acute kidney injury during autologous stem cell transplantation in AL amyloidosis. , 2021, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[5] S. Sarosiek,et al. Organ responses after highdose melphalan and stemcell transplantation in AL amyloidosis , 2020, Leukemia.
[6] D. Dingli,et al. Safety and efficacy of propylene glycol-free melphalan as conditioning in patients with AL amyloidosis undergoing stem cell transplantation , 2018, Bone Marrow Transplantation.
[7] A. Dispenzieri,et al. Systemic immunoglobulin light chain amyloidosis , 2018, Nature Reviews Disease Primers.
[8] G. Doros,et al. Predictive value of the new renal response criteria in AL amyloidosis treated with high dose melphalan and stem cell transplantation , 2018, American journal of hematology.
[9] P. Hari,et al. Use of propylene glycol-free melphalan conditioning in light-chain amyloidosis patients undergoing autologous hematopoietic cell transplantation is well tolerated and effective , 2018, Bone Marrow Transplantation.
[10] D. Dingli,et al. Stem Cell Transplantation for Light Chain Amyloidosis: Decreased Early Mortality Over Time. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] M. Bayliss,et al. A longitudinal evaluation of health‐related quality of life in patients with AL amyloidosis: associations with health outcomes over time , 2017, British journal of haematology.
[12] G. Doros,et al. The incidence of atrial fibrillation among patients with AL amyloidosis undergoing high-dose melphalan and stem cell transplantation: experience at a single institution , 2017, Bone Marrow Transplantation.
[13] P. Hari,et al. A Phase IIb, Multicenter, Open-Label, Safety, and Efficacy Study of High-Dose, Propylene Glycol-Free Melphalan Hydrochloride for Injection (EVOMELA) for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[14] D. Seldin,et al. Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation: 20-year experience. , 2015, Blood.
[15] A. Foli,et al. A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. , 2014, Blood.
[16] K. Finn,et al. Hospital admissions following outpatient administration of high-dose melphalan and autologous SCT for AL amyloidosis , 2014, Bone Marrow Transplantation.
[17] Z. Bhat,et al. Severe Propylene Glycol Toxicity Secondary to Use of Anti-Epileptics , 2014, American journal of therapeutics.
[18] J. McGuirk,et al. Phase IIa cross-over study of propylene glycol-free melphalan (LGD-353) and alkeran in multiple myeloma autologous transplantation , 2014, Bone Marrow Transplantation.
[19] G. Doros,et al. Safety and efficacy of high-dose melphalan and auto-SCT in patients with AL amyloidosis and cardiac involvement , 2014, Bone Marrow Transplantation.
[20] M. Skinner,et al. High-dose melphalan and stem cell transplantation for patients with AL amyloidosis: trends in treatment-related mortality over the past 17 years at a single referral center. , 2012, Blood.
[21] M. Dimopoulos,et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] M. Skinner,et al. Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients. , 2011, Blood.
[23] M. Guglin,et al. Melphalan‐Induced Supraventricular Tachycardia: Incidence and Risk Factors , 2011, Clinical cardiology.
[24] D. Dingli,et al. Autologous stem cell transplant for immunoglobulin light chain amyloidosis: a status report , 2010, Leukemia & lymphoma.
[25] M. Perazella,et al. Reviews: Recognition, Treatment, and Prevention of Propylene Glycol Toxicity , 2007, Seminars in dialysis.
[26] K. Wilson,et al. Clinical Investigations in Critical CarePropylene Glycol Toxicity: A Severe Iatrogenic Illness in ICU Patients Receiving IV Benzodiazepines: A Case Series and Prospective, Observational Pilot Study , 2005 .
[27] R. Falk,et al. High-Dose Melphalan and Autologous Stem-Cell Transplantation in Patients with AL Amyloidosis: An 8-Year Study , 2004, Annals of Internal Medicine.
[28] J. Fish,et al. Propylene Glycol‐Associated Renal Toxicity from Lorazepam Infusion , 2003, Pharmacotherapy.
[29] M. Skinner,et al. Incidence and outcome of acute renal failure complicating autologous stem cell transplantation for AL amyloidosis. , 2003, Kidney international.